Novo Nordisk Weight Loss Drug
-
{
- All
- News
- Videos
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
- Thursday May 14, 2026
- Health | Written by Sambhav Kumar
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
www.ndtv.com
-
Dr Reddy's Wins Nod to Sell Generic Ozempic, Check Cost Of Weight-Loss Drug
- Wednesday April 29, 2026
- India News | Edited by Prateek Shukla
The entry of Dr Reddy's generic is triggering a price battle among pharmaceutical companies worldwide.
-
www.ndtv.com
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
- Tuesday April 14, 2026
- Health | Reported by Tanushka Dutta
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
www.ndtv.com
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
- Thursday April 2, 2026
- Science | Edited by Nikhil Pandey
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
www.ndtv.com
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
- Thursday March 19, 2026
- Health | Reported by Tanushka Dutta
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
www.ndtv.com
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
- Wednesday March 18, 2026
- Health | Satviki Sanjay, Bloomberg
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
www.ndtv.com
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
- Friday February 27, 2026
- Health | Reported by Tanushka Dutta
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
www.ndtv.com
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
- Monday February 23, 2026
- Health | Reported by Tanushka Dutta, Edited by Debosmita Ghosh
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
www.ndtv.com
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
- Monday February 9, 2026
- Health | Written by Tanushka Dutta
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
www.ndtv.com
-
Weight Loss Pill Wegovy Now Available On Amazon Pharmacy In The U.S.
- Sunday January 11, 2026
- Health | Written by Tanushka Dutta
Amazon Pharmacy maintains the requirement for a valid prescription as the central safeguard separating evidence-based medical therapy from consumer health products.
-
www.ndtv.com
-
Diabetes, Weight Loss Drug Ozempic Launched In India: See Dosage, Price And More
- Friday December 12, 2025
- Health | Indo-Asian News Service
Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four weeks.
-
www.ndtv.com
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
- Friday December 12, 2025
- India News | Reuters
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
www.ndtv.com
-
Novo Nordisk Partners With Emcure To Launch Weight Loss Drug Poviztra In India
- Tuesday November 11, 2025
- Health | Press Trust of India
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a semaglutide injection 2.4 mg for weight loss, the statement said.
-
www.ndtv.com
-
Weight-Loss Breakthrough: Drug Cuts Heart Risk Even If You Don't Shed Kilos
- Thursday October 23, 2025
- Science | Edited by Nikhil Pandey
A large-scale study shows semaglutide reduces heart risks regardless of weight loss, suggesting the drug benefits cardiovascular health in more ways than previously thought. The findings highlight waist size as a stronger indicator of heart improveme
-
www.ndtv.com
-
Novo Nordisk's Ozempic Is Launching In India, Country Head Calls It A "Welcome Change"
- Tuesday September 30, 2025
- Lifestyle | Written by Arushi Bidhuri
Danish drugmaker Novo Nordisk's India Head, Vikrant Shrotiya, shares that the pharmaceutical giant is ready to launch Ozempic in India
-
www.ndtv.com/lifestyle
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
- Thursday May 14, 2026
- Health | Written by Sambhav Kumar
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
www.ndtv.com
-
Dr Reddy's Wins Nod to Sell Generic Ozempic, Check Cost Of Weight-Loss Drug
- Wednesday April 29, 2026
- India News | Edited by Prateek Shukla
The entry of Dr Reddy's generic is triggering a price battle among pharmaceutical companies worldwide.
-
www.ndtv.com
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
- Tuesday April 14, 2026
- Health | Reported by Tanushka Dutta
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
www.ndtv.com
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
- Thursday April 2, 2026
- Science | Edited by Nikhil Pandey
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
www.ndtv.com
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
- Thursday March 19, 2026
- Health | Reported by Tanushka Dutta
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
www.ndtv.com
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
- Wednesday March 18, 2026
- Health | Satviki Sanjay, Bloomberg
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
www.ndtv.com
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
- Friday February 27, 2026
- Health | Reported by Tanushka Dutta
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
www.ndtv.com
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
- Monday February 23, 2026
- Health | Reported by Tanushka Dutta, Edited by Debosmita Ghosh
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
www.ndtv.com
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
- Monday February 9, 2026
- Health | Written by Tanushka Dutta
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
www.ndtv.com
-
Weight Loss Pill Wegovy Now Available On Amazon Pharmacy In The U.S.
- Sunday January 11, 2026
- Health | Written by Tanushka Dutta
Amazon Pharmacy maintains the requirement for a valid prescription as the central safeguard separating evidence-based medical therapy from consumer health products.
-
www.ndtv.com
-
Diabetes, Weight Loss Drug Ozempic Launched In India: See Dosage, Price And More
- Friday December 12, 2025
- Health | Indo-Asian News Service
Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four weeks.
-
www.ndtv.com
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
- Friday December 12, 2025
- India News | Reuters
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
www.ndtv.com
-
Novo Nordisk Partners With Emcure To Launch Weight Loss Drug Poviztra In India
- Tuesday November 11, 2025
- Health | Press Trust of India
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a semaglutide injection 2.4 mg for weight loss, the statement said.
-
www.ndtv.com
-
Weight-Loss Breakthrough: Drug Cuts Heart Risk Even If You Don't Shed Kilos
- Thursday October 23, 2025
- Science | Edited by Nikhil Pandey
A large-scale study shows semaglutide reduces heart risks regardless of weight loss, suggesting the drug benefits cardiovascular health in more ways than previously thought. The findings highlight waist size as a stronger indicator of heart improveme
-
www.ndtv.com
-
Novo Nordisk's Ozempic Is Launching In India, Country Head Calls It A "Welcome Change"
- Tuesday September 30, 2025
- Lifestyle | Written by Arushi Bidhuri
Danish drugmaker Novo Nordisk's India Head, Vikrant Shrotiya, shares that the pharmaceutical giant is ready to launch Ozempic in India
-
www.ndtv.com/lifestyle